FDA Updates CLIAC On Diagnostic Guidance Pipeline, Co-Development Trends
This article was originally published in The Gray Sheet
Executive Summary
FDA's drug center increasingly consults with the Office of In Vitro Diagnostic Device Evaluation & Safety regarding in vitro diagnostics used to support drug clinical trials, according to OIVD staffer Jean Cooper
You may also be interested in...
Larger Clinical Studies Required To Assess Device Risk/Benefit – Duke’s Califf
A rethinking of the U.S. clinical trials system is needed to truly understand the risks and benefits of current and future devices and drugs, Duke Clinical Research Institute Director Robert Califf, MD, asserted at the FDA Science Forum April 28
Larger Clinical Studies Required To Assess Device Risk/Benefit – Duke’s Califf
A rethinking of the U.S. clinical trials system is needed to truly understand the risks and benefits of current and future devices and drugs, Duke Clinical Research Institute Director Robert Califf, MD, asserted at the FDA Science Forum April 28
ASR Guidance Development May Be Supported By AdvaMed FAQ Document
AdvaMed plans to revise a set of frequently asked questions related to analyte specific reagents that could be used as a starting point for an FDA guidance document, following a recent meeting with the agency